ANGLE 将来の成長

Future 基準チェック /26

ANGLEは、55.3%と51.5%でそれぞれ年率55.3%で利益と収益が成長すると予測される一方、EPSはgrowで55.5%年率。

主要情報

55.3%

収益成長率

55.5%

EPS成長率

Medical Equipment 収益成長	22.5%
収益成長率	51.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	21 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

AIM:AGL - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	36	-6	N/A	-6	2
12/31/2025	17	-14	-10	-11	2
12/31/2024	8	-16	-10	-12	2
6/30/2024	2	-18	-13	-12	N/A
3/31/2024	2	-19	-14	-13	N/A
12/31/2023	2	-20	-15	-14	N/A
9/30/2023	2	-21	-16	-15	N/A
6/30/2023	2	-22	-16	-15	N/A
3/31/2023	1	-22	-17	-16	N/A
12/31/2022	1	-22	-18	-16	N/A
9/30/2022	1	-19	-19	-17	N/A
6/30/2022	1	-17	-19	-18	N/A
3/31/2022	1	-16	-18	-16	N/A
12/31/2021	1	-15	-16	-14	N/A
9/30/2021	1	-15	-13	-12	N/A
6/30/2021	1	-16	-11	-10	N/A
3/31/2021	1	-14	-10	-9	N/A
12/31/2020	1	-12	-8	-8	N/A
6/30/2020	1	-10	-14	-15	N/A
3/31/2020	1	-11	-14	-14	N/A
12/31/2019	1	-11	-13	-13	N/A
10/31/2019	1	-10	-11	-9	N/A
7/31/2019	1	-9	-10	-8	N/A
4/30/2019	1	-9	-9	-7	N/A
1/31/2019	1	-9	-9	-7	N/A
10/31/2018	1	-8	-9	-7	N/A
7/31/2018	1	-8	-9	-7	N/A
4/30/2018	1	-8	N/A	-7	N/A
10/31/2017	0	-7	N/A	-8	N/A
7/31/2017	0	-7	N/A	-8	N/A
4/30/2017	0	-7	N/A	-7	N/A
10/31/2016	1	-5	N/A	-5	N/A
7/31/2016	0	-5	N/A	-5	N/A
4/30/2016	0	-5	N/A	-4	N/A
1/31/2016	0	-5	N/A	-4	N/A
10/31/2015	N/A	-4	N/A	-4	N/A
7/31/2015	N/A	-4	N/A	-4	N/A
4/30/2015	N/A	-4	N/A	-3	N/A
10/31/2014	-1	-3	N/A	-3	N/A
7/31/2014	0	-3	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A
1/31/2014	2	-1	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AGL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AGL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AGL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AGLの収益 ( 51.5% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: AGLの収益 ( 51.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AGLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ANGLE 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

ANGLE plc Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

ANGLE plc Provides Earnings Guidance for the Year 2023

Price target decreased by 35% to UK£0.94

Recent updates

Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR

New major risk - Share price stability

Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer